― 216 ―Acad. Sci. USA., 120, e2304943120, (2023).2. Saito Y, Iida-Norita R, Tania A, Refaat A, Hazama D, Komori S, Ohata S, Takai T, Oduori OS, Kotani T, Funakoshi Y, Koma Y, Murata Y, Yakushijin K, Matsuoka H, Minami H, Yokozaki H, Manz MG, Matozaki T: Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models. Front. Immunol., 14, 1294814 (2023).3. Sakamoto M, Murata Y, Tanaka D, Kakuchi Y, Okamoto T, Hazama D, Saito Y, Kotani T, Ohnishi H, Miyasaka M, Fujisawa M, Matozaki T: Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages. Proc. Natl. Acad. Sci. USA., 119, e2109923118, (2022).4. Okamoto T, Murata Y, Hasegawa D, Yoshida M, Tanaka D, Ueda T, Hazama D, Oduori OS, Komori S, Takai T, Saito Y, Kotani T, Kosaka Y, Maniwa Y, Matozaki T: Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis. Cancer Sci., 114, 1871–1881 (2023).
元のページ ../index.html#218